Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer

0 Comments 2 view(s)

Company Also Added Key Members to the Senior Management Team

  • Barbara Ruskin J.D. Ph.D. Appointed SVP, General Counsel and Chief Patent Officer
  • Nenad Sarapa M.D. M.S. Appointed SVP of Clinical Development
  • Conrad Jordaan Appointed SVP of Finance and Corporate Controller

AUSTIN, Texas, Nov. 14, 2017 (GLOBE NEWSWIRE) — Molecular Templates, Inc., (NASDAQ:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), today announced the appointment of Adam Cutler as Chief Financial Officer, effective Monday, November 13, 2017.  Mr. Cutler will report to Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates, and will be responsible for all corporate finance, accounting, and investor relations activities.

“Adam’s corporate biotechnology experience and knowledge of the industry as well as his investment banking experience will be of great value to Molecular Templates,” said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates.  “We are very fortunate to have someone of his caliber and record of achievement join our team and we look forward to the strategic insights and contributions he will make.”  

“I am excited to join Molecular Templates at this important time for the company,” said Adam Cutler, Molecular Templates’ newly appointed Chief Financial Officer. “Molecular Templates is developing an entirely new class of anti-cancer therapeutics, based on its proprietary ETBs technology, that possess differentiated mechanisms of action in oncology.”

“I am also pleased to announce three key additions to the management team.  Dr. Barbara Ruskin is our new General Counsel and Chief Patent Officer, Dr. Nenad Sarapa is our Senior Vice President of Clinical Development, and Conrad Jordaan is our Senior Vice President of Finance and Corporate Controller.  I am looking forward to all of their contributions to the growth and success of Molecular Templates, and welcome them to the team,” added Dr. Poma.

Adam Cutler is a biotechnology executive with over 20 years of experience in equity research, investor relations, capital markets advisory, business development, finance, and management consulting.  Prior to joining Molecular Templates, he was Senior Vice President of Corporate Affairs for Arbutus Biopharma, responsible for designing and executing investor relations programs as well as contributing to the company’s business development and corporate finance efforts. From 2012-2015, he was a Managing Director for The Trout Group LLC and Trout Capital LLC, where he executed financings and advised public and private life science companies on …

Full story available on Benzinga.com